GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Interest Expense

Affymax, (FRA:A5Y) Interest Expense : €0.00 Mil (TTM As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Affymax, Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Affymax,'s interest expense for the three months ended in Jun. 2014 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2014 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Affymax,'s Operating Income for the three months ended in Jun. 2014 was € -0.75 Mil. Affymax,'s Interest Expense for the three months ended in Jun. 2014 was € 0.00 Mil. Affymax, has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Affymax, Interest Expense Historical Data

The historical data trend for Affymax,'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Interest Expense Chart

Affymax, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.11 -0.11 -1.10 -1.14

Affymax, Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 - - - -

Affymax, Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymax,  (FRA:A5Y) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Affymax,'s Interest Expense for the three months ended in Jun. 2014 was €0.00 Mil. Its Operating Income for the three months ended in Jun. 2014 was €-0.75 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2014 was €0.00 Mil.

Affymax,'s Interest Coverage for the quarter that ended in Jun. 2014 is calculated as

Affymax, had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Affymax, (FRA:A5Y) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines